MIX BULK 350

PRODUCT OVERVIEW

Specification	Details
Generic Name	**Bulk Mix 350**
Drug Class	**Anabolic-Androgenic Steroid Blend**
Active Ingredient	**Trenbolone Enanthate / Testosterone Enanthate / Boldenone Undecylenate**
Administration Route	**Intramuscular Injection**
Dosage Form	**Injectable Oil-Based Solution**
Total Concentration	**350 mg/mL**
Primary Target	**Androgen Receptor**
Clinical Status	**Non-Approved Multi-Compound Anabolic Steroid Formulation**

INTRODUCTION

Bulk Mix 350 is a multi-compound injectable anabolic-androgenic formulation containing Trenbolone Enanthate 100 mg/mL, Testosterone Enanthate 175 mg/mL, and Boldenone Undecylenate 125 mg/mL, providing a total active concentration of 350 mg/mL.

The formulation combines three esterified androgens with relatively prolonged release characteristics. Trenbolone is a potent 19-nortestosterone-derived androgen, Testosterone represents the principal endogenous androgen, and Boldenone is a synthetic testosterone-derived anabolic-androgenic steroid. All three compounds exert significant biological activity through androgen-receptor signaling while maintaining distinct metabolic and pharmacokinetic characteristics.

HISTORY

The components of Bulk Mix 350 originate from different areas of androgen pharmacology. Testosterone Enanthate was developed as a longer-acting testosterone preparation and remains an established testosterone ester in medical practice. Boldenone Undecylenate was first introduced in veterinary medicine. Following ester hydrolysis, the three components release their respective active hormones: trenbolone, testosterone, and boldenone.

CHEMICAL STRUCTURE

Bulk Mix 350 combines three esterified steroidal compounds: Trenbolone Enanthate is the enanthate ester of trenbolone, a 19-nortestosterone derivative, while Testosterone Enanthate is formed through esterification of the 17β-hydroxyl group of testosterone with enanthoic acid.

Boldenone Undecylenate is the undecylenate ester of boldenone, a testosterone-derived anabolic-androgenic steroid distinguished by an additional double bond in its steroid structure. Following ester hydrolysis, the three components release their respective active hormones: trenbolone, testosterone, and boldenone.

CHEMICAL PROFILE

Parameter	Information
Primary Components	**Trenbolone Enanthate, Testosterone Enanthate, Boldenone Undecylenate**
Hormone Classification	**Anabolic-Androgenic Steroid Blend**
Administration	**Intramuscular Injection**
Dosage Form	**Oil-Based Injectable Solution**
Total Concentration	**350 mg/mL**
Ester Profile	**Enanthate + Enanthate + Undecylenate**

PHARMACOLOGY

Bulk Mix 350 combines three esterified anabolic-androgenic compounds whose principal biological activity involves androgen-receptor signaling.

Following intramuscular administration, the esterified compounds are gradually released from the oil depot. The mechanism involves:

- Release of the three esterified compounds from the intramuscular depot
- Enzymatic hydrolysis of the enanthate and undecylenate ester groups
- Release of trenbolone, testosterone, and boldenone
- Binding of active hormones to intracellular androgen receptors
- Activation and nuclear translocation of androgen-receptor complexes
- Regulation of androgen-responsive gene transcription
- Modification of protein metabolism and androgen-sensitive cellular activity

MECHANISM OF ACTION

Following intramuscular administration, the esterified compounds are gradually released from the oil depot.

The mechanism involves:

- Release of the three esterified compounds from the intramuscular depot
- Enzymatic hydrolysis of the enanthate and undecylenate ester groups
- Release of trenbolone, testosterone, and boldenone
- Binding of active hormones to intracellular androgen receptors
- Activation and nuclear translocation of androgen-receptor complexes
- Regulation of androgen-responsive gene transcription
- Modification of protein metabolism and androgen-sensitive cellular activity

PHARMACODYNAMICS

Bulk Mix 350 affects multiple physiological systems through combined androgen-receptor signaling.

SKELETAL MUSCLE SYSTEM

Anabolic-androgenic steroids interact with androgen receptors in skeletal muscle and may influence:

- Protein metabolism
- Muscle tissue maintenance
- Nitrogen retention
- Myogenic differentiation

Androgen-receptor signaling contributes to the regulation of normal skeletal muscle structure and function.

SKELETAL SYSTEM

Androgen-receptor signaling contributes to skeletal physiology and may influence:

- Bone metabolism
- Skeletal maintenance
- Bone mineralization
- Structural integrity

CONNECTIVE TISSUE

Androgen-receptor signaling may influence connective tissue physiology through:

- Structural protein metabolism
- Tissue maintenance
- Tissue remodeling
- Collagen metabolism

REPRODUCTIVE SYSTEM

Androgenic compounds interact with androgen-sensitive tissues and may influence:

- Hormonal regulation
- Endocrine signaling
- Reproductive physiology
- Androgen-responsive tissues

PHARMACOKINETICS

Following intramuscular administration, Bulk Mix 350 forms an oil-based depot from which the esterified compounds are gradually released.

The enanthate, enanthate and Testosterone Enanthate contain enanthate esters that provide prolonged release compared with short esters such as acetate or propionate. Boldenone Undecylenate contains a longer undecylenate ester and consequently demonstrates particularly prolonged depot release.

Because the formulation contains three distinct esterified compounds, Bulk Mix 350 does not have one universal pharmacokinetic half-life. Its overall activity represents overlapping release profiles of trenbolone, testosterone, and boldenone.

PHYSIOLOGICAL EFFECTS

Bulk Mix 350 produces combined androgenic activity through trenbolone, testosterone, and boldenone. Activation of androgen receptors in skeletal muscle and other androgen-responsive tissues can influence protein synthesis, nitrogen balance, muscle protein turnover, erythropoiesis, skeletal physiology, and general androgen-dependent cellular function. The longer ester chains may produce sustained release rather than the comparatively rapid exposure associated with short-ester formulations.

The three components also possess distinct secondary metabolic characteristics. Testosterone can undergo aromatization to estradiol and conversion to DHT. Boldenone can undergo aromatization but differs from testosterone in its metabolic behavior, while trenbolone does not undergo meaningful aromatization. Combined exposure may therefore influence endocrine, hematological, cardiovascular, reproductive, and hepatic systems through several overlapping pathways.

CLINICAL APPLICATIONS

The individual components have different pharmacological histories. Testosterone Enanthate has established medical applications in androgen replacement and selected androgen-deficiency conditions. Boldenone Undecylenate has primarily been associated with veterinary applications, while contemporary Trenbolone Enanthate formulations do not have an established approval for human therapeutic indication.

The specific combination of Trenbolone Enanthate 100 mg/mL, Testosterone Enanthate 125 mg/mL, and Boldenone Undecylenate 125 mg/mL does not have an established approved human therapeutic indication.

SAFETY CONSIDERATIONS

The use of anabolic-androgenic steroids may require consideration of cardiovascular, hematological, hepatic, endocrine, metabolic, and reproductive health.

Important safety considerations include:

- Cardiovascular health
- Blood pressure
- Hematological parameters
- Lipid profiles
- Liver function
- Endocrine function
- Reproductive function
- Prostate health

The overall safety profile depends on the specific compound, formulation, concentration, duration of exposure, individual response, and personal characteristics. Appropriate medical evaluation and regular monitoring should be considered when clinically indicated.

POTENTIAL ADVERSE EFFECTS

Potential adverse effects associated with anabolic-androgenic steroid exposure may involve endocrine, cardiovascular, hematological, hepatic, dermatological, reproductive, and metabolic systems.

Endocrine Effects
- Suppression of endogenous hormone production
- Alterations in hormonal balance
- Changes in reproductive hormone signaling
- Potential suppression of spermatogenesis

Cardiovascular Effects
- Changes in lipid profile
- Possible increases in blood pressure
- Potential cardiovascular risk

Hematological Effects
- Changes in hematocrit
- Changes in hemoglobin
- Possible increase in erythropoietic activity

Dermatological Effects
- Acne
- Increased sebaceous activity
- Androgen-related hair loss in genetically predisposed individuals

Reproductive Effects
- Changes in reproductive function
- Potential reduction in fertility
- Alterations in reproductive hormone regulation

Hepatic & Metabolic Effects
- Changes in liver function parameters
- Alterations in metabolic markers
- Changes in glucose and lipid metabolism

The occurrence and severity of adverse effects vary according to the specific compound, formulation, exposure, duration of use, individual response, and patient characteristics.

CONTRAINDICATIONS

Condition	Reason
Prostate Cancer	**Potential androgen sensitivity**
Male Breast Cancer	**Risk of fetal virilization**
Pregnancy	**Potential worsening of cardiovascular risk**
Severe Cardiovascular Disease	**Requires specialist evaluation**
Severe Hepatic or Renal Disease	**Potential further increase in hematocrit**

DRUG INTERACTIONS

A comprehensive interaction profile may not be established for every anabolic-androgenic steroid or formulation.

Potential interactions or clinical considerations may exist with:

- Anticoagulants
- Hepatotoxic medications
- Hepatic medications
- Other anabolic-androgenic steroids
- Other hormonal therapies
- Drugs affecting lipid metabolism

The clinical significance of potential interactions depends on the specific compound, formulation, dosage, duration of exposure, concomitant medications, and individual patient characteristics. Appropriate medical evaluation should be considered when multiple medications or hormonal therapies are used concurrently.

LABORATORY MONITORING

Laboratory Test	Purpose
CBC	**Monitor hematological parameters**
ALT / AST	**Liver function**
Bilirubin	**Hepatic assessment**
Lipid Profile	**Cardiovascular risk assessment**
Blood Pressure	**Cardiovascular monitoring**
Total Testosterone	**Assess androgen status**
LH / FSH	**Assess endocrine suppression**

STORAGE & STABILITY

- Store according to official product labeling.
- Protect from excessive heat and direct sunlight.
- Do not freeze.
- Maintain original packaging integrity.
- Keep away from children.
- Inspect packaging before use.

PRODUCT AUTHENTICITY

Every genuine NEXON product should include appropriate quality verification features.

Authentication may include:

- Batch number tracking
- Manufacturing information
- Expiration date verification
- QR authentication system
- Authorized distributor verification

NEXON emphasizes transparency, traceability, and product quality control.

FREQUENTLY ASKED QUESTIONS

What is Bulk Mix 350?
Bulk Mix 350 is a multi-compound injectable formulation containing Trenbolone Enanthate 100 mg/mL, Testosterone Enanthate 125 mg/mL, and Boldenone Undecylenate 125 mg/mL.

What is the total concentration?
The total active concentration is 350 mg/mL.

Are all three components long-acting?
They all use relatively long ester structures. Trenbolone and Testosterone contain enanthate esters, while Boldenone contains the longer undecylenate ester.

Do all three components release the same hormone?
No. They release three different active hormones: trenbolone, testosterone, and boldenone.

Which components can aromatize?
Testosterone can aromatize to estradiol. Boldenone also has aromatizable activity, while trenbolone does not undergo conventional aromatization to estrogen.

Is Trenbolone a 19-nortestosterone derivative?
Yes. Trenbolone belongs to the 19-nortestosterone structural family.

NEXON QUALITY COMMITMENT

NEXON is committed to maintaining high standards of manufacturing quality, product consistency, traceability, and scientific transparency.

Through quality control systems, authentication procedures, and responsible information sharing, NEXON aims to provide reliable pharmaceutical products and educational resources for healthcare professionals and informed users.

SCIENTIFIC REFERENCES

1. Kicman AT. Pharmacology of Anabolic Steroids.

2. Basaria S. Androgen Abuse in Athletes: Detection and Consequences.

3. Handelsman DJ. Androgen Physiology and Pharmacology.

4. Shahidi NT. Chemistry, Biological Action and Clinical Applications of Anabolic-Androgenic Steroids.

5. Llewellyn W. Anabolics.

6. Evans NA. Current Concepts in Anabolic-Androgenic Steroids.

7. Kochakian CD. Anabolic-Androgenic Steroids.

8. Nieschlag E, Behre HM. Andrology: Male Reproductive Health and Dysfunction.

9. Kicman AT, Gower DB. Anabolic Steroids in Sport and Exercise.

10. Wilson JD. Androgen Physiology and Pharmacology.